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Abstract High-throughput screening (HTS) is an effec-
tive method for lead and probe discovery that is widely
used in industry and academia to identify novel chemical
matter and to initiate the drug discovery process. How-
ever, HTS can be time consuming and costly and the use
of subsets as an efficient alternative to screening entire
compound collections has been investigated. Subsets may
be selected on the basis of chemical diversity, molecular
properties, biological activity diversity or biological tar-
get focus. Previously, we described a novel form of subset
screening: plate-based diversity subset (PBDS) screening,
in which the screening subset is constructed by plate selec-
Electronic supplementary material The online version of this
article (doi:10.1007/s11030-016-9692-9) contains supplementary
material, which is available to authorized users.
B Jeremy R. Everett
j.r.everett@greenwich.ac.uk
1 Pfizer Worldwide Research and Development, Groton, CT,
USA
2 Pfizer Worldwide Research & Development, Sandwich, Kent,
UK
3 Present Address: Imperial College, London, UK
4 Present Address: Scitegrity Ltd, Discovery Park, Sandwich,
Kent, UK
5 Present Address: University of Greenwich, Chatham
Maritime, Kent, UK
6 Present Address: JL Consulting, Deal, Kent, UK
7 Present Address: Eli Lilly & Company, Indianapolis, IN, USA
8 Present Address: Sandexis Medicinal Chemistry Ltd,
Canterbury, Kent, UK
9 Present Address: RES Consulting, San Francisco Bay, CA,
USA
10 Present Address: Ipsen, Slough, Berkshire, UK
tion (rather than individual compound cherry-picking), using
algorithms that select for compound quality and chemi-
cal diversity on a plate basis. In this paper, we describe a
second-generation approach to the construction of an updated
subset: PBDS2, using both plate and individual compound
selection, that has an improved coverage of the chemi-
cal space of the screening file, whilst only selecting the
same number of plates for screening. We describe the val-
idation of PBDS2 and its successful use in hit and lead
discovery. PBDS2 screening became the default mode of sin-
gleton (one compound per well) HTS for lead discovery in
Pfizer.
Keywords Rule of 40 · Ro40 · High-throughput screening
(HTS) · Plate-based · Diversity · Subset · Screening file ·
2nd Generation · Lead discovery
Abbreviations
cAMP Cyclic adenosine monophosphate
cLogP Calculated logarithm to base 10 of partition
coefficient P of compound between n-octanol
and water
ECFP4 SciTegic/Accelrys’ level 4 extended connec-
tivity fingerprints
FE File enrichment
GDRS Global diverse representative subset
HTS High-throughput screening
PBDS Plate-based diversity subset
PBDS2 Plate-based diversity subset generation 2
PMC Parallel medicinal chemistry
SAR Structure–activity relationships
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Introduction
The pharmaceutical industry is undergoing a period of
significant change that is characterized by site closures,
reduction in research and development (R&D) operations,
an increased use of outsourcing as opposed to in-house oper-
ations, increased collaboration with academic partners and
an increased focus on biological agents as well as small
molecules [1–3]. These changes are driven by the discon-
nect between the rising investments in drug discovery R&D
and the decline in new drug outputs [4]. This poor produc-
tivity has been attributed to project attrition, which has been
especially acute in Phase II of the development process [5],
where project survival as low as 10 % has been recorded.
Many proposals for improving the current situation have
been proposed [6–11], and although a significant increase
in new drug approvals has been reported over the past two
years [12,13], all elements of the drug discovery process
are nevertheless being scrutinized. An operation such as
high-throughput screening (HTS) [14–16] not only requires
expensive hardware for screening itself, but also requires sig-
nificant investments in the compound collection, thematerial
management processes to create, store and access the file,
the informatics system to underpin all these efforts and, of
course, the expert scientists to operate it. In large companies,
it is common for the screening file to comprise millions of
compounds [17,18]. An HTS against such a file could take
several months to screen and cost a considerable amount in
terms of reagents, consumables and staff time. It is therefore
natural for drug discovery scientists to investigate faster and
cheaper options for lead discovery that might have similar
success rateswith greater efficiency. Several approaches have
been explored including virtual screening [19–22], where the
screening event is entirely in silico, or fragment screening
[23–26] where the low molecular weight of the fragment
compounds used for lead discovery means that a larger per-
centage of the chemical space can be covered with far fewer
compounds than for a conventional screening file of larger
compounds. Virtual screening has the advantages of speed
and low costs; however, the probable success of virtual
screening against a novel target, or against a target for which
only an apo structure is available [27], will be low due to
the difficulties of predicting ligand–target interactions in the
absence of structural information on that complex. Fragment
screening is highly effective and becoming increasingly so,
even against novel targets, but suffers from the drawbacks
of generally finding weak binding hits and the fact that hit
follow-up is hindered unless supported by structural biology
information to guide the chemist.
Much effort has also gone into improving the efficiency of
HTS approaches themselves including the use of (i) diverse
subset screening [28,29], where a portion of the file is
selected to represent the entire file on the basis of chemical
diversity [30]; (ii) targeted subset approacheswhere a portion
of the file is selected on the basis of the predicted increased
likelihood of finding active compounds against a specific tar-
get or target gene family [31,32] using existing knowledge
and (iii) compressed screening [33,34] where compounds
are mixed together into pools such that far fewer wells need
to be screened, depending on the degree of compression.
These approaches have the efficiency benefit of screening
fewer wells. However, there are potential drawbacks to all
these approaches in terms of success rates. Diverse subset
approaches can suffer from the issue of selecting for bizarre
outlier compounds, unless care is taken with the selection
algorithm, and will always be inferior to screening the full
file, because potentially active compounds are being dese-
lected for screening. Targeted subset approaches will only
be as good as the knowledge base used to make the selection
and will suffer from the additional issue of failing to find hits
that are in novel or in non-obvious areas of chemical space.
Compressed screening approaches suffer from the combined
problems of increased compound load, directly proportional
to the number of compounds in each well, and of potential
compound interactions in the mixtures, which can lead to
high false-positive rates and potentially false negatives as
well.
In order to find new solutions to the problem of increasing
HTS efficiency, we introduced a novel plate-based diver-
sity subset (PBDS) for singleton (one compound per well)
HTS in Pfizer in 2006 [35] and Novartis reported on simi-
lar implementations in 2007 [36] and 2009 [37]. The PBDS
was constructed by a novel process that (i) selected only
high-quality screening plates that were Rule of 40 (Ro40)
[35] compliant, (ii) used a random-based plate selection
process to avoid false minima in the optimization of plate
selection and (iii) was programmed to provide a double
coverage of >95 % of the BCUT [38] chemical space
of the 2006 Pfizer screening file in a minimal number of
plates (around one-eighth the number of screening plates
of the entire file). We now report on the design, valida-
tion and successful use of an improved, second-generation,
plate-based diversity subset (PBDS2). An update to the
first subset selection was necessary, as the original PBDS
had become out of date, with the significant growth of the
Pfizer screening file between 2006 and 2009. However, in
creating PBDS2, we took the opportunity to not only sam-
ple new chemical space, but also to enhance significantly
the selection methodology and design, such that the new
PBDS2 provides a double coverage of 100 % of the BCUT
chemical space of the enlarged screening file, whilst only
using the same number of plates as the original PBDS.
PBDS2became the standardmethod of singleton-HTS-based
lead discovery in Pfizer after its introduction in 2009 and
here we describe its design, implementation and initial suc-
cesses.
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Results
Construction of the plate-based diversity subset
generation 2 (PBDS2)
The Pfizer screening file
The Pfizer screening file in the fourth quarter of 2008
comprised ca 10,198 plates (384-well) and ca 3.7 million
compounds. The plates were processed using the following
four steps prior to the selection of plates for the PBDS2. As in
the original PBDSconstruction [35], theGlobalDiverseRep-
resentative Subset (GDRS) filters [28] were applied to flag
and then remove compounds with undesirable substructures
or properties. Similarly, duplicate compounds and com-
pounds with any structural ambiguity were also removed.
1. A list of plate identifiers (IDs) was processed to generate
compound IDs for each compound on each screening
plate.
2. Compound IDs were translated into chemical structures
(SMILES, Simplified Molecular-Input Line-Entry Sys-
tem).
3. SMILES were checked for uniqueness.
4. Structural filters [Global Diverse Representative Subset
(GDRS)] [28,35] were applied to identify and computa-
tionally ‘remove’ compounds with unwanted (reactive or
otherwise bad) functionality.
The 3,263,170 remaining, well-defined, non-duplicate,
filter-pass compounds (89 % of the total set) were used for
the analysis and were processed in the following way:
1. Rule of 5 (Ro5) [39] properties for each compound were
calculated and summarized on a plate basis.
2. The number of unique compounds on each plate was
determined (compounds that had failed the GDRS filters
were not counted).
3. Stricter structural filters [35,40] were applied on each
individual compound and the number of compounds free
of these structural alerts on each plate was calculated.
4. Five-dimensional BCUT [38] coordinates were calcu-
lated for each individual compound and BCUT sum-
maries generated for each plate.
5. Each compound was classified as being derived via par-
allel or library chemistry (via its library ID) or through
non-library synthesis (absence of library ID) and these
classifications were summed up for each plate.
Screening plate quality for PBDS2 plate selection:
The 384-well screening plates selected for the original PBDS
[35] were all compliant with the Rule of 40 (Ro40). This was
to ensure that only plates of the highest quality were included
into this critical subset, which was the mainstay of singleton
screening in Pfizer from 2006. Each screening plate contains
up to 360 test compounds and has the remaining 24 positions
reserved for control compounds. TheRo40 [35] specifies that
in order to be compliant, a 384-well plate must have
(1) more than 200 unique test compounds,
(2) more than 160 test compounds with zero Ro5 [39] viola-
tions and
(3) more than 120 test compounds free of any undesirable
structural alerts [40]
These rules weremodified andmade stricter for PBDS2 plate
selection as follows (see Experimental section for details):
(1) remove plates with very low numbers (<200) and penal-
ize plates with low numbers (<300) of unique com-
pounds passing the GDRS filters;
(2) remove plates with very high numbers (>300) and
penalize plates with high numbers (>160) of total Ro5
violations, summed up across the plate;
(3) remove plates with very high numbers (>100) and penal-
ize plates with high numbers (>30) of compounds failing
the stricter structural filters [35,40];
(4) give combinatorial plates an initial advantage in the selec-
tion process but remove this advantage in the final opti-
mization iterations to achieve convergence (see below);
(5) remove all plates already in PBDS in order to avoid plate
depletion issues [41].
Experience from constructing the PBDS subset [35], which
was very successful in practice, had shown that plates in
violation of the Ro40 which were severely penalized (their
assigned random number received a penalty of +1.0) in the
seeding process never got selected. Therefore, we felt con-
fident that we could exclude unacceptable plates completely
without loss of important chemical space.
In addition, we now applied moderate penalties to less
desirable plates, according to stricter rules, in order to better
prioritize the property space in PBDS2. A moderate penalty
of 0.1 was added to the random number assigned, ensuring
that these plates would not be in the top 10 % of plates in
the random order. This was justified as any critical chemical
space lost could be replaced through the later cherry-picked
portion of the new PBDS2 selection process (see below). A
similar moderate advantage of −0.1 was initially given to
library plates to allow them a higher chance of selection.
Figure 1a shows a histogramof the number of unique com-
pounds on each 384-well plate in the screening collection in
November 2008. 98.5 % of the screening plates contain 200
or more compounds on and would therefore not be removed
by the first rule of the PBDS2 plate selection process. Fig-
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Fig. 1 a Histogram of the number of screening plates in the Pfizer
Screening File containing 0 to 40, 41 to 80, 81 to 120, etc. unique
compounds per 384-well plate. The maximal number of test wells per
plate is 360, as 24 wells are reserved for controls. b Histogram of the
number of plates containing a total of 0 to 100, 101 to 200, etc. Ro5
violations per plate: note that any given compound on a plate could
have more than one violation. c Histogram of plates containing 0 to 40,
41 to 80, etc. compounds per plate failing the stricter structural filters
and thus being undesirable to a medicinal chemist. All data for Pfizer
screening file as of 4th Quarter 2008.
ure 1b shows the number of plates with 0 to 100, 101 to 200,
etc. total Ro5 violations. Only 2 % of the plates have at least
300 Ro5 violations associated with them (maximum possi-
ble number of violations per plate = 360 × 4 = 1440) and
would therefore be removed by the second rule. In addition,
Figure 1c shows the number of compounds on each plate that
fail the stricter structural filters [35,40]. This demonstrates
that the vast majority of plates would also not be removed by
rule 3 of the PBDS2 plate selection rules.
Theprocess outlined abovewasused to removeor penalize
plates. Removed plates were not considered again during
the selection process. Penalized plates got a penalty in the
random seeding of plate orders that ensured they were only
selected if the same region of space could not be adequately
covered by non-penalized plates: see Experimental section
for more details.
BCUT chemical space for PBDS2 plate selection
Weelected touseBCUTsas implemented inDiverseSolutions®
[42] to define the chemical space of the screening file in pref-
erence to fingerprints or molecular framework approaches,
as this had worked very well for the design of the original
PBDS [35]. We chose the cell-based BCUT approach [38]
that provides both inter-compound distances and absolute
positions in defined chemistry space and enables effectively
all diversity tasks. In designing PBDS2, a five-dimensional
(5D) chemistry space was used (a 6D space was used for
PBDS) as it best represented compound diversity and yielded
the most uniform distribution of compounds in the BCUT
space. At the same time, we increased the number of bins in
the 5D space from the 8 used in the PBDS, to 12. Based on
an analysis of diversity distributions for each of the BCUT
metrics, we found that including the BCUT metric of hydro-
gen bond acceptor would introduce both many empty cells
and many highly dense cells and therefore was considered
as an improper metric to use for describing the diversity of
the compound collection. Removing this less-relevant met-
ric and increasing the number of bins resulted in a similar
total number of BCUT cells describing the chemical space
of the screening file (248,832 vs. 262,144 in the original
PBDS analysis) but an increase in the percentage of occu-
pied cells and a reduction in the number of cells occupied by
high numbers of compounds, thus producing a more evenly
distributed chemical space. This lowers the randomness of
selection within highly occupied cells, as well as the occur-
rence of relatively diverse compounds randomly occupying
the same cell. Overall, this resulted in amore even and diverse
subset.
As for the original PBDS, we chose to define the tar-
get chemical space of the screening file to be covered as
those BCUT cells with an occupancy of 10 compounds or
more. This was in order to avoid optimization of the PBDS2
screening subset on compounds with unusual structures in
low-occupancy cells [35].
In the original PBDS, our target was to achieve a double
coverage of >95 % of the BCUT cells with 10 or more com-
pounds in them, i.e. the PBDS would contain at least two
compounds from >95 % of the BCUT cells with an occu-
pancy of ≥ 10 compounds. Double coverage of the BCUT
cells was selected to mitigate against two factors: (i) HTS is a
noisy detector and could generate a false-negative result and
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Fig. 2 Percentage of screening plates against the binned number (0 to
40, 41 to 80, etc.) of library compounds on each plate in the filtered
Pfizer screening file as of November 2008. The polarization of plates
into those derived from library chemistry and those not is clear
(ii) there is inherently still a diversity of compounds within
each cell. For PBDS2 in contrast to PBDS, we wanted to
achieve a double coverage of 100% of the cells with an occu-
pancy ≥10 compounds, in order to ensure that the set had an
improved representation of the chemical space of the file as a
whole. This improvement is difficult to achieve using plate-
based selection alone, as the iterations achieve a diminishing
return at high percentage cell coverage, so we investigated
a hybrid approach with a plate-based subset augmented by
cherry-picking of individual compounds in order to achieve
complete double coverage of BCUT space.
Pfizer screening file: library and non-library compounds
The original 2006 file analysis ahead of the creation of PBDS
showed that the file was polarized between plates that con-
tained mostly library chemistry compounds with low overall
chemical space diversity, together with plates containing
mostly non-library compounds with much higher chemical
space diversity [35]. This plate-type distribution has impor-
tant consequences for the selection of a plate-based diverse
subset, as the library plates tend to have low BCUT space
coverage relative to non-library plates and therefore tend
not to be selected for a diversity-based subset. We there-
fore re-analysed the enlarged file in November 2008. This
analysis (Fig. 2) showed that whilst the proportion of library
compound-containing plates had grown (ca 60% of plates in
2008 containing in excess of 160 library compounds versus
ca 54 % in 2006), the screening file was still very largely
polarized into plates containing mostly library compounds
and those containing mostly non-library (singleton or array)
compounds.
Quality of compounds vs activity
A recent publication [43] describes a selection process using
plate-based biological activity in previous screening cam-
paigns as the main driver to derive an optimal plate-based
Fig. 3 A plot of General Activity vs Rule of 5 scores for multiple,
diverse screening sets [44]. The closed black diamonds are for exter-
nal company or organization libraries. The open yellow square is for
known drugs. See Experimental section for definitions and calculations
of General Activity and Rule of 5 scores
selection for screening purposes. Prior to the PBDS2 work,
we had developed a scoring scheme for Pfizer virtual libraries
and for external compound collections to distinguish promis-
ing collections and libraries from potentially less successful
ones. The scoring scheme was based on mapping a large
number of individual compounds into chemical space and
statistically determining areas of enrichment in biological
activity in the chemical space. The scheme worked for any
other property associated with individual compounds.
Mapping the scores for biological activity of multiple,
external, commercial compound collections available in
2008 versus the score for Ro5 compliance generated an unex-
pected result [44].
We found a near-perfect linear inverse correlation between
good scores for activity and good scores for Ro5 space for
all compound collections (Fig. 3). Similar trends were found
for biological activity score against clogP, molecular weight
and molecular solubility. The only true outlier to all these
trends was the drug collection, implying that drugs have an
enhanced combination of biological activity and properties.
With hindsight, this result should not have been surprising:
the process of going fromhit to lead and from lead to drugwill
inevitably discard compounds with inferior activity/property
combinations. In addition, the difficulty of combining good
physical properties with excellent activity in a drug molecule
is well known [45–48].
It is unlikely that a simple algorithm will be able to drive
compound SAR directly into drug space and thereby break
through the above correlation. It therefore becomes a ques-
tion of strategy. Is it better to start drug discovery projects
with compounds with good properties and improve on their
activity, or start with very active compounds and improve
their properties?
Our strategy was based on the experience that it is eas-
ier to increase potency than it is to build in good properties.
We also recognized that combinatorial chemistry offers a
more efficient follow-up mechanism. We therefore deliber-
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ately did not use activity data during the selection process as
this would lead us away from the Ro5 space and the combi-
natorial chemistry space. This strategy was consistent with
our focus on the discovery of lead-like compounds [49,50].
PBDS2 Plate selection for optimal BCUT space coverage
The iterative plate selection algorithm used for PBDS2 plate
selection was developed from the methodology [35] used
for the original PBDS. An initially random plate order was
chosen to avoid false minima in the selection of the final
plate order. The plate order was then optimized in an iterative
process that used the number of additional BCUT cells cov-
ered by new plates as the fitness function (see Experimental
section for further details). The new developments made for
this implementation relative to that used for PBDS were as
follows. The necessity to select equal numbers of library and
non-library plates embedded into the PBDS plate selection
algorithmwas removed for PBDS2. Library chemistry plates
were initially given an advantage in the selection process
to give them a higher chance to be picked. However, this
preferential treatment of library plates was removed after 80
% of iterations were completed to allow convergence based
purely on optimal BCUT space coverage. This preferred
treatment of combinatorial plates was applied to ensure that
high-quality combinatorial plates would have the best chance
to be selected in preference to non-combinatorial plates cov-
ering a similar BCUT chemical space, as hit follow-up of
library compounds is facile. At the same time, removing the
previous restrictions on a fixed ratio between combinatorial
and non-combinatorial plates ensured that non-combinatorial
plates would be selected once combinatorial plates no longer
covered the unmapped space in an economical way.
The PBDS2 plate selection achieved a single coverage
of ca 97 % and >99 % and a double coverage of ca 90 %
and >95 % of target BCUT cells from the selection of the
best 800 and 1000 plates, respectively (Fig. 4), a consider-
able improvement upon the original PBDS [35], where 1200
plates were required to provide a double coverage of 95.4 %
of the same target BCUT cells of a smaller file.
In order to achieve a double coverage of 100%of the target
BCUT space efficiently, and especially to ensure that PBDS2
had good coverage of library compounds, we added a cherry-
picked element to PBDS2. A variety of targeted cherry-pick
approaches were investigated, including the selection of rep-
resentative compounds from clusters inside unrepresented
BCUT cells. In this trial approach, the “fill-in” approach
of DiverseSolutions® [42] was used for the cherry-picking.
However, no targeted method worked as well as a fully
random cherry-pick of compounds from the portion of the
screening file that was not represented in the plate-pick (see
Supplementary Fig. 1 and Supplementary Tables 1 and 2 for
further information).
Fig. 4 A plot of the number of BCUT cells in the Pfizer screening
file covered for the first time (single coverage, upper dark blue line)
and second time (double coverage, lower, pink line), plotted against the
number of 384-well screening plates selected. Note the convergence of
the iterative plate selection algorithm after the selection of 1200 plates.
(Color figure online)
In silico validation of plate-based diversity subset
generation 2 (PBDS2) approaches
The PBDS2 subsetting approach was validated using a ret-
rospective in silico analysis of hit series retrieval against ca
68,000 confirmed actives with IC50 values of <10 µM from
77 recent singleton HTSs run in the period prior to PBDS2
design at Pfizer. These 77 HTSs were executed against a
broad range of targets in both biochemical and cell-based
assays. The in silico series retrieval testing was performed
against three different scenarios, each involving 400,000
selected compounds: (i) 100 % plate-based set, (ii) 75 %
plate-based/25 % cherry-picked set and (iii) a 50 % plate-
based and 50 % cherry-picked set. In the latter two cases, the
cherry-pick was done randomly against all compounds not
yet selected by the preceding iterative plate selection process.
In each case, the 400,000 compounds represented 11 % of
the full Pfizer file at that time (Table 1).
Figure 5 shows two elements: Firstly, a series of curves
were calculated using Belief Theorymethods, as applied pre-
viously in our molecular redundancy work [17], to calculate
the percentage of series that should be found on a proba-
bilistic basis, taking into account cluster size, by randomly
screening different sized subsets of the Pfizer screening file.
As would be expected, the probability of series retrieval
rises sharply with the size of each series/cluster, calculated
here for a series of between 1 and 50 compounds. Sec-
ondly, superimposed on these six curves are two vertical
lines showing the series retrievals for a test PBDS2 subset of
400,000 compounds composed 50 % of plate-based and 50
% of cherry-picked compounds (random cherry-picking of
compounds not selected in the plate-pick). The 50/50 plate-
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Table 1 The composition of the
Pfizer screening file in fourth
quarter 2008 prior to the
construction of PBDS2
File Number of
plates
Number of
compound
IDs
Number of
SMILES
Number of
unique
SMILES
Number
passing
GDRS filters
Singleton 384 well 8998 3,239,280 3,041,481 3,040,455 2,848,710
PBDS [35] 1200 432,000 422,704 422,685 414,460
Total 10,198 3,671,280 3,664,185 3,463,140 3,263,170
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Fig. 5 Calculation of the number of HTS hit series that would be
expected to be found by random screening of between 0 and 20 %
of the screening file for a series of cluster sizes of between 1 and
50 compounds (curves). Superimposed on these graphs are the cal-
culated performances (shown by vertical lines) of a PBDS2 subset of
400,000 compounds when tested in silico against 68,000 HTS hits with
IC50 < 10µM from 77 recent HTSs and covering a range of cluster
sizes, based on different molecular similarity criteria. The test PBDS2
subset in this case was constructed 50 % from plate-based selection fol-
lowed by 50 % from random cherry-picking from those compounds not
yet selected by the plate-pick. The vertical lines show the percentage of
series that this PBDS2 construct was calculated to retrieve for a series
of at least 1 active (light blue) and for a series of at least 5 actives (blue).
See Supplementary Fig. 2 and Supplementary Tables 1 and 2 for more
information. (Color figure online)
based/cherry-picked composition of this test PBDS2 set was
used to test the success of the overall concept, with the final
PBDS2 composition being determined later (see below). Two
ranges of expected percentage series retrieval are given: one
for a scenario where all series have at least 5 active com-
pounds and the other for a scenario where the series can have
any size from a singleton active upwards. In each case, the
range of percent series found is based on calculations using
single-linkage clustering with Tanimoto similarity bound-
aries of 0.6, 0.7, 0.8 and 0.9 (Supplementary Table 2). It is
clear that for this test PBDS2 design of 400,000 compounds
(11 % of the screening file), that series retrieval for all series
(including singletons) is between 23 and 30 %. However,
for larger series of 5 or more compounds, the in silico cal-
culated series retrieval rises to between 69 and 83 %; an
approximately 6- to 7-fold enhancement relative to random
screening of 11 % of the whole file.
We then analysed different ratios of plate-picked to cherry-
picked compounds for the final design of PBDS2. Table 2
below shows that the retrieval of all series varied only slightly
from33 to 31%and then to 27%as the plate selection portion
is reduced from 100 to 75 % and then to 50 % of the subset.
However, the coverage of larger series (5 ormore compounds
per series) increases more significantly from 67 % to 74 %
and then 75 %, respectively, and the percentage of libraries
covered increases dramatically from 17 to 100 % and 100 %,
respectively.
The final design for the PBDS2 was chosen to be 75%
plate-picked and 25 % random cherry-picked from the
remaining compounds not selected from the plate-pick.
The final selection comprised 1200 plates: 900 from the
plate-pick and 300 from the cherry-pick. This design was
chosen for the following reasons: (i) the library cover-
age was dramatically improved over the subset designed
with 100 % plate-picking; (ii) the efficiency of finding all
series was only slightly reduced relative to the 100 % plate-
picked design, (iii) the efficiency of finding larger series
was superior to that of the 100 % plate-picked design and
almost equivalent to that of the 50/50 plate-picked/cherry-
picked design and (iv) the significant reduction in material
management resources required to pick ca 108,000 com-
pounds (25 %) relative to 216,000 (50 % of the set). The
selected PBDS2 set had a total of 308,833 compounds
from plate selection and 108,000 compounds from cherry-
picking, totalling 416,833 compounds that comprised 11.4%
of the screening file. The flow chart (Fig. 6) provides a
simplified overview of the entire PBDS2 plate selection
process.
Properties of the plate-based diversity subset generation
2 (PBDS2)
Target chemical space coverage of the selected PBDS2
plates
The selection process resulted in
1. 100 % double coverage of the BCUT space of the 2009
file (Table 3),
2. a representation of non-library compounds vs library
compounds of approximate 2:1, compared to a forced
1:1 representation in the original PBDS [35],
3. 100 % coverage of all libraries due to the cherry-picked
portion of the selection and
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Table 2 An overview of the calculated series retrieval and fold effi-
ciency, and the actual library coverage of three PBDS2 designs of
400,000 compounds with 100, 75 and 50 % of the subsets chosen by
iterative plate selection (see above) and the balance chosen by random
cherry-picking from the remaining compounds not selected in the plate
selection process
Percentage of plate-based/cherry-picked set in test PBDS2s 100/0 75/25 50/50
% Of total series found 33 31 27
% Of larger series found (≥5 actives) 67 74 75
% Of libraries covered at ≥level of
GDRS2, a 2nd generation
cherry-picked subset [28] of
150,000 compounds used by
therapeutic area teams
17 100 100
Fold efficiency over full file singleton for finding larger series 6.1 6.7 6.8
The series retrieval is calculated as described previously against 68,000 active compounds with IC50 ≤ 10µM, found in 77 recent Pfizer HTSs
Fig. 6 A flow chart depicting the five main stages of the PBDS2 plate selection process
4. a significantly increased hit rate compared to a random
selection of screening compounds (see Fig. 5 in Sect. 3.2
above).
Property distributions of the compounds selected in PBDS2
The 1200 plates of the PBDS2 that were selected were
analysed to ensure that the distribution of molecular and
calculated properties of the compounds in the subset was
satisfactory and at least comparable with those of the origi-
nal PBDS [35], especially for cLogP where high values had
caused the majority of the original PBDS Rule of 5 fail-
ures. The average cLogP and molecular weights in PBDS2
were 3.02 and 367 Da against the values of 3.27 and 380 Da,
respectively, for the original PBDS. The percentage of com-
pounds with 0 and 1 Rule of 5 failures were 85.9 and 11.5 %
in PBDS2 compared with 87% and 11%, respectively, in the
original PBDS. The percentages of neutrals, bases and acids
in PBDS2 was 60.6, 30.5 and 8.9 %, respectively. Further
information is provided in Supplementary Fig. 2.
Hit and series discovery using PBDS2 in live screening
campaigns
The PBDS2 subset was utilized in more than 25 HTS cam-
paigns over the subsequent 3-year period at which time a
new version of the subset was created to avoid plate deple-
tion caused by unanticipated non-HTS use of the initial
segment of the PBDS2 [40]. The HTS campaigns included
Table 3 An analysis of the cell occupancies in PBDS2
PBDS2 BCUT cell analysis
BCUT cell compound population Number of BCUT cells
1–20 31,727
21–40 2584
41–60 948
61–80 517
81–100 307
101–120 195
121–140 124
141–160 80
161–180 59
181–200 33
201–220 32
221–240 22
241–260 19
261–280 8
281–300 6
301–320 6
321–340 2
341–360 1
361–380 0
381–400 1
Total number of occupied cells 36,671
Average occupied cell population 11.2
Standard deviation of
average
occupied cell population
7.2
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Fig. 7 Compound 5 above from Zhang et al. [51] was an early
lead developed from a PBDS2 subset hit and has mGluR5 Ki =
6.60 nM, Geometric mean, n ≥ 3 measurements in HEK-293FT cells
expressing human mGLUR5 using [3H]MPEPy ([3H]3-methoxy-5-
pyridin-2-ylethynylpyridine); mGLUR5 IC50 = 14.5 nM Geometric
mean, n ≥ 3 measurements in HEK-293 cells expressing rat mGluR5
using fluorimetric imaging plate reader (FLIPR)
both cell-based and biochemical approaches, covered a broad
range of target types including kinases, G-protein-coupled
receptors (GPCRs), ion channels, transcription factors, epi-
genetic factors, a variety of enzymes and protein–protein
interactions, and included phenotypic approaches measur-
ing known, clinically relevant endpoints. The GPCR targets
were addressed via multiple approaches including both bind-
ing and functional screens to identify a variety of agonists,
inverse agonists and allosteric modulators.
A screen of the PBDS2 subset was run at 10µM com-
pound concentration using transfected HEK293 cells and a
calcium flux format to search for negative allosteric modu-
lators of the metabotropic glutamate receptor 5 (mGluR5).
This campaign successfully identified multiple active series
including a novel series of pyrazolopyrimidines that have
been reported and described in detail [51] (Fig. 7).
Additional GPCR screens in alternate formats were also
successful in identifying valid actives.A screen of thePBDS2
at 10µM compound concentration for agonists of GPR119
using a cAMP readout yielded a 0.8%primary hit rate at>40
%activity. Subsequent screening of the parental cellwas used
to eliminate false positives and a beta-arrestin screenwas also
used in hit triage. The known lead matter was active and 4
novel series were identified for chemistry pursuit until the
project was terminated for strategic reasons.
A second agonist screen for compounds modulating
GPR120 was run at 20µM compound concentration in a
beta-arrestin format and yielded a 1 % primary hit rate at
>20 % activity. Non-selective matter was eliminated using
an alternate GPCR target. The screen identified previously
known chemical matter but the project team did not pur-
sue these compounds as they were seeking material with
greater brain penetration. A total of 5 novel series were
also identified, 3 of which were pursued into hit-to-lead
phase, until the program was terminated for strategic rea-
sons.
A screen of the PBDS2 was undertaken for inhibitors of
the serine hydrolase, monoacylglycerol lipase (MAGL), as
potential therapeutics for neuroinflammatory disease. The
screen used a previously described, biochemical assay [52].
Compounds were screened at 10µMconcentration and mul-
tiple lead series were identified including compounds that
were demonstrated to have competitive covalent and com-
petitive non-covalent mechanisms of action. The irreversible
azetidine carbamates have been disclosed in a previous
presentation [53]. Binding to the target protein has been con-
firmed through x-ray crystallography and the series has been
pursued to advanced stages with active chemistry design and
synthesis.
Multiple PBDS2 screens for epigenetic factor inhibitors
using an alphascreen format have been plagued with false
positives. Following one screen targeting the epigenetic
reader, BRD4, elimination of many of these spurious com-
pounds was achieved with a fluorescence polarization assay
leaving approximately 100 true actives of interest. One
of the primary hits from the PBDS2 subset demonstrated
IC50 < 200 nM in the polarization assay and subsequently
displayed activity in cell-based assays of humanwhole blood
and human peripheral blood mononuclear cells, indicating
the ability of the library to identify matter that translates to
more physiologically relevant systems. In a second example,
targeting a lysine demethylase eraser protein, selected com-
pounds from the 22,000 primary hits were triaged through a
high-throughputmass spectrometry assay and approximately
780 compounds achieved >50 % activity at 10µM concen-
tration. A total of 604 compounds yielded IC50 < 10µM,
providing further examples of translation to orthogonal tech-
nologies.
In another program searching for activators of the TREK-
1 potassium channel, a high-throughput, compressed format
thallium flux assay (9.1µM per compound) yielded no
series of interest for medicinal chemistry. As a result, the
PBDS2 was screened, since the high-quality singleton col-
lection enabled a higher screening concentration to be used
(22.4µM). This campaign successfully yielded a 0.5 % pri-
mary hit rate with multiple series, making the translation to
electrophysiology screens.
One campaign for protein upregulationutilized apromoter-
driven reporter readout in a disease-relevant cell line. The
PBDS2 collection was screened yielding a 0.5 % primary
hit rate for compounds demonstrating >30 % effect. These
compoundswere subsequently tested in an orthogonal screen
confirming protein expression (Delfia format). Approxi-
mately 12 % of the initial hits confirmed in the secondary
assay and more than 100 compounds were demonstrated to
have EC50 values<10µM. From these compounds, a total of
38 were selected and used to seed hit expansion efforts from
the full chemical file, generating an additional 10,000 com-
pounds that were profiled in the reporter assay with a 7.5 %
hit rate. A total of 128 of these hit expansion compounds had
>15 % activity at 10µM in the orthogonal assay and ulti-
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mately 13 compounds were validated by the project team.
These compounds were ultimately not pursued into devel-
opment since they were subsequently shown to be acting
via transcriptional pathways that yielded undesirable adverse
effects.
Not all screens were so successful; two campaigns for
oncology indications screened against protein–protein inter-
actions yielded no hits that were suitable for chemistry
follow-up. One tested the PBDS2 subset and additional mat-
ter in bothfluorescence polarization and alphascreen formats.
The second also tested multiple chemical libraries with dif-
ferent variations of an Alphalisa readout. The druggability of
both targets has been called into question. A third protein–
protein interaction for oncology also failed to yield hits from
a scintillation proximity assay that tested both the PBDS2
and a commercially available file. A legacy Wyeth screen
for the same target in Delfia format also failed to produce
validated hit matter. None of the 3 files appeared to con-
tain any analogues of the only publically known series at the
time.
Discussion
Need for a second-generation PBDS
PBDS had been successful as a default subset of 429,067
compounds for lead finding by singleton HTS since its intro-
duction in Pfizer in 2006. By late 2008, a large number of new
compounds had been added to the screening file from library
synthesis, individual compound synthesis and compound and
company purchases. There was therefore a need to update the
PBDS to ensure that it remained representative of the chemi-
cal space of the enlarged screeningfile and adesire to improve
upon its chemical space coverage. The PBDS design had
included a fixed alternate selection of library and non-library
plates in order to ensure that the valuable library chemistry
that Pfizer had invested so much resource in was repre-
sented in the subset. However, because library plates tend
to be rather non-diverse, this stipulation meant that the effi-
ciency of chemical space coverage was non-optimal, as some
of the library plates selected for PBDS were non-diverse
and contained compounds that with new understanding, we
now regarded as structurally redundant [17]. Re-plating the
complete file was not an option, as it was far too large amate-
rial management task. We needed a new process that would
select suitable representatives of these library compounds but
avoid the selection of entire plates full of very similar com-
pounds from one or more libraries. We thus abandoned the
requirement for alternate selection of library and non-library
plates for PBDS2 and moved to a new, hybrid selection
approach.
Selection of the screening plates for PBDS2
The double coverage of target BCUT space for PBDS2 rel-
ative to PBDS was much improved, as the requirement to
select equal numbers of library and non-library plates was
removed. As a consequence of this change, library plates
with low additional BCUT space coverage tended not to
get selected. We therefore experimented with the notion of
supplementing the plate-picked portion of the subset with a
cherry-picked portion that would serve to fill in the holes of
BCUT space missed by the plate selection algorithm and,
in particular, to ensure that every individual library in our
screening file was represented in PBDS2. This was relatively
easy to monitor and execute as all library compounds have a
unique identifier specific to each different library design, as
well as a unique compound identifier. An analysis of series
retrieval statistics gave excellent results for a 75/25 % plate-
pick/cherry-pick design (Table 2). The fold efficiency for
the retrieval of larger series relative to full file screening
increased from 6.1-fold to 6.7-fold in progressing from a
100 % plate-pick design to a 75 % plate-pick/25 % cherry-
pick design. This large improvement in screening efficiency
is attributed to the 75/25%PBDS2 design being better able to
retrieve larger series that include library compounds. In the
100 % plate-pick design, some library compounds may be
either overrepresented and redundant, e.g. through selection
of a plate dominated by a single library, or missing altogether
due to non-selection of non-diverse library plates.
The final design was implemented with random cherry-
picking from all of the compounds that had not been selected
in the initial iterative plate-pick of 900, 384-well plates.
Intuitively, we felt that a deterministic cherry-pick based
on choosing compounds representative of clusters from the
unpicked compounds should be a superior methodology to
random selection. However, extensive in silico analysis of
active series retrieval showed that random cherry-picking
outperformed our clustering methods, in every configura-
tion of cluster similarity and cluster size that we analysed
(see Supplementary Fig. 1 and Supplementary Tables 1 and
2 for further data). We therefore implemented PBDS2 with
25 % random cherry-picking from those compounds in the
screening file unselected following the iterative plate-pick.
Performance of the PBDS2
PBDS2 replaced PBDS as the default singleton screening
subset for Pfizer therapeutic area targets in July 2009. Over
the next 3 years, the subset was successfully used in more
than 25HTScampaigns, against a very broad range of targets,
some of which are presented in the Results section. Addi-
tionally, PBDS2 was used for more phenotypic approaches
capturing broader mechanisms of action measuring known,
clinically relevant endpoints. If actives were found in a
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PBDS2 screen, the follow-up process was generally as fol-
lows: (1) confirm the activity of the putative hits with repeat,
single-concentration assays; (2) measure the IC50 values of
confirmed hits; (3) perform ‘hit expansion’ around selected
confirmed hits using similarity searching in the remainder of
the screening file to locate compounds with similar structural
features to those hits and then screening them and finally (4)
initiate de novo synthesis projects to follow up promising
hit series. Whilst the selection of plates for PBDS2 used the
Rule of 5 as one quality measure for plates of compounds
as a whole, the selection of confirmed hits for follow-up
would normally require compounds to pass stricter require-
ments including the Rule of 4 (molecular weight <400Da;
cLogP < 4.0, less than 4 hydrogen bond donors and less than
8 hydrogen bond acceptors). This is because it is well known
that in progressing from hit to lead to drug candidate, that
molecularweight and lipophilicity tend to increase and there-
fore the starting hits are preferentially selected to be of lower
molecular weight and lipophilicity than that which is opti-
mal for drugs. The performance of the PBDS2 was excellent,
generating high-quality hit series that translated to physio-
logically relevant systems and formed the basis for medicinal
chemistry design and synthesis [51,53]. Demand for access
to this newly prioritized plate-based diverse subset was so
great that eventually the material management stocks, which
had been designed to last for ten years, became depleted and
a complementary subset approach PBDSx was subsequently
introduced to mitigate this [41].
Conclusions
Plate-based diversity subset (PBDS) screening was a novel
approach when introduced into Pfizer in 2006. It is a radical
new approach that changes HTS from random screening to
a deterministic, chemical space-based paradigm. It quickly
became the defaultmethod for singletonHTS inPfizerGlobal
R&Dandwas highly successful. The new, second-generation
PBDS2 represents an important development in subset design
as it enables the capture of value from relatively low-diversity
library series, without resorting to forcing the selection of
library plates, as had been done in the original PBDS imple-
mentation [35]. In addition, the hybrid design of PBDS2,
with the majority of the subset derived from iterative plate-
picking, but 25 % derived from random cherry-picking of
the remaining, non-selected compounds, enables the facile
updating of the subset over time. All that is required is that,
at intervals, new plates are added to the subset by judi-
cious cherry-picking of compounds occupying new regions
of BCUT space, as the plates containing those compounds
are registered into the screening file. Like its predecessor,
PBDS2 became the default subset for singletonHTS in Pfizer
Global R&D following its introduction in 2009, on the basis
of its simplicity of construction and its 6.7-fold greater effi-
ciency in large series retrieval relative to full file singleton
screening. In addition to the overall concept of PBDS, we
believe that the randomly initiated plate selection algorithm
and the plate selection rules presented here will be of utility
to many academic and industrial drug discovery groups as
they create new subsets for HTS [30,32,54].
The success of PBDS [35] and then PBDS2 in Pfizer over
many years [51,53] and the parallel success of the Novartis
methods [36,37] give us confidence that this approach will
be of value for HTS of large screening files for many years
to come. Indeed, a new approach to the plate selection algo-
rithm has recently emerged from Novartis, where plates are
selected principally according to the biological target diver-
sity profile of the compounds on the plates [43].Anewvariant
has also emerged from Pfizer, where, due to increased use of
PBDS2 and differential plate depletion, a novel methodol-
ogy for the construction of several equivalent PBDSs was
developed [41]. We look forward to further developments to
improve drug discovery efficiency in the future.
Experimental
Dataset
The file analysis was performed on the Pfizer Screening File
containing 10,198 singleton screening plates available for
experimental screening from Pfizer Material Management
as of autumn 2008. Each 384-well screening plate contained
up to 360 test wells and 24 control positions. Information for
each individual plate was in the form of compound identifiers
mapped to well positions. This information was transformed
into structure information using the Pfizer internal compound
database. Batch information was ignored at this stage and
only the desalted compound structure was used.
The screening plates came from multiple compound
sources: Legacy Pfizer (including Warner Lambert), Pfizer
library chemistry (File Enrichment, external, combinator-
ial compounds), Pfizer parallel medicinal chemistry (PMC,
internal, combinatorial and non-combinatorial [33]) and
legacy Pharmacia [17].
Property calculations
Computational work on the dataset was carried out using
Pipeline Pilot® from SciTegic/Accelrys [55]. File filters
were applied as previously described [35]. Compound iden-
tities and duplication were assessed using the simplified
molecular-input line-entry system or SMILES from Day-
light Chemical Information Systems Inc [56]. Compounds
with identical salt-free canonical SMILES were classified
as duplicates. Rule of 5 properties were based on internal
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code with clogP values based on the BioByte code from
Pomona College [57]. The chemical space occupancy of
compounds on the screening plates was calculated using the
BCUT methodology from DiverseSolutions®, supplied by
Tripos Inc [42], as previously described [35] but with modi-
fication; see below.
Series definitions
Compound clusteringwas performedusingBarnard 1052fin-
gerprints from Barnard Chemical Information Systems Ltd
(30 Kiveton Lane, Todwick, Sheffield UK) and Tanimoto
similarity metrics calculated using Daylight [56] fingerprint
comparison tools. Each compound was assigned to a cluster
if it had a Tanimoto similarity above a given threshold (0.6,
0.7, 0.8 or 0.9) to at least one other member in the cluster.
HighTanimoto values result in a large number of singleton
compounds, while low Tanimoto values reduce significantly
the number of singleton and result in larger clusters. Both
descriptions have advantages and disadvantages and there-
fore the analysis was performed across the range of different
similarity values given above.
Chemical space definition
In designing PBDS2, a five-dimensional (5D) chemistry
space was defined for our corporate collection using the
“auto-choose” algorithm in DiverseSolutions® [42]. This
chemistry space is different from the 6D space used for the
original PBDS (we removed the BCUT metric of hydrogen
bond acceptor), but gives amore uniformdistribution of com-
pounds in the BCUT space. At the same time, we increased
the number of bins in the BCUT space from 8, as used in the
PBDS, to 12 for PBDS2.
General activity and Rule of 5 (Ro5) score definitions
The activity score and the Ro5 score methodologies were
developed to compare and evaluate external compound
datasets without the need to exchange structural data. BCUT
space was used to describe the chemical space. The first
step divided the chemical space into small bins – the indi-
vidual BCUT cells. A background set was mapped into
this space to represent the sort of compounds produced
in the pharmaceutical industry. The Pfizer HTS screen-
ing file was used for this purpose as the best available
set.
A reference set representing compounds with a specific
quality or property was then mapped into the same space.
The quality of the reference set was measured with binary
outputs such as yes/no for a property such as biological activ-
ity, solubility or Ro5 compliance at a set level. This allowed
the calculation of a score for each individual bin, i.e. BCUT
cell, representing the relative density of compounds in the
reference set with a particular property compared to the back-
ground set. A scaling factor was used to map reference sets
of different sizes.
A score for any other test set could then be generated
by mapping each individual test compound with a specific
property set to yes into the reference set and calculating the
average score of all of the compounds in the test set. The
scaling factor k is given by
k = N
A
.
The score for individual bin i is then given by
scorei = k × Ai
k × Ai + Ni
…and the averaged score for the test set is given by
scoretest = 1
B
×
B∑
i=1
scorei × Bi ,
where N is the total number of compounds in back-
ground set, in this case, the Pfizer screening file; Ni is
the number of compounds of background set in cell i ;
A is the total number of compounds in reference set;
Ai is the number of compounds of the reference set
in cell i ; B is the total number of compounds in test
set; Bi is the number of compounds of test set in cell
i .
The reference set used for the activity score was a set of
ca. 60,000 known active compounds (activity<10µM) from
the Pfizer Drug Store database. The scoring method works
well with a comprehensive reference set with broad chemical
space coverage.
The Ro5 score was calculated by exactly analogous meth-
ods but using Ro5 compliance instead of biological activity
as the property. Compliance was defined as complying with
all of the Ro5 rules. This differs from the original Ro5 that
allowed a single failure but was more in line with the stricter
use of the rule in this work at Pfizer. Both the Ro5 score
and the general activity score are scaled relative to the back-
ground file.
PBDS2 plate selection
The PBDS2 plate selection used an iterative process with the
following workflow implemented into Pipeline Pilot:
1. Individual plate statistics were derived prior to the selec-
tion process including the number of unique compounds
on each plate, the total sum of Ro5 violations on each
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plate, the number of structural alert failures and the num-
ber of library compounds. Plates with >50 % library
compoundswere designated as library plates – thesewere
given a bonus in the seeding process (see below).
2. All plates belonging to the original PBDS set [35] were
excluded from the selection process. Plates of insufficient
quality were removed prior to the selection stage (see
“Results” section). Plates that had worse-than-average
properties (see 1.2 as well) were given a penalty in the
seeding process.
3. Each plate was allocated a random number prior to the
first iteration, with a value between 0 and 1. Combinato-
rial plates received a bonus to this random number value
(−0.1), while plates with undesirable properties received
a penalty (+0.1).
4. Plates were ordered from low to high random number
and it was determined how many new, unoccupied, or
singly occupied BCUT cells each plate contributed. This
value was highly order dependent and drove the use of
the random ordering process.
5. The plates were then reordered according to the number
of new BCUT cells filled for the first or second time.
6. New random numbers were then created for all plates.
The top 50 plates from the first iteration retained their
position, while all other plates were resorted according
to their new random number, from low to high.
7. The number of newly filled BCUT cells was recalculated
and all plates were again resorted according to this target
function (number of newBCUT cells covered for the first
or second time). This resorting included the original top
50 plates, which could now slowly drop in the ranking if
fitter plates were present with greater additional BCUT
space coverage.
8. The top 100 plates were retained after the second itera-
tion and an additional 50 plates were retained after each
subsequent iteration up to a maximum number of 800
retained plates.
9. All constraints in terms of plate score bonuses and penal-
ties were removed after 50 iterations and a final 20
iterations were performed.
The total number of iterations required was determined
through two test runs using 20 and 50 iterations in the absence
of any constraints. The partly constrained process detailed
above converged more slowly but to a better solution than
the unconstrained processes.
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